Study guide
23.3 Mental Capacity & UK Mental Health Law
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
23.3 Mental Capacity & UK Mental Health Law
Key Takeaways Explain This Topic AI
Capacity requires the patient to understand, retain, weigh and communicate the decision; failure of any one limb means capacity is absent for that decision.
Section 5(2) allows a doctor to detain an already-admitted inpatient for up to 72 hours; section 5(4) is a nurse's holding power for up to 6 hours.
The Mental Health Act cannot be used to treat a physical condition unless it is the direct cause or consequence of the mental disorder; otherwise the Mental Capacity Act applies.
Last updated: September 2026
5. Mental Capacity & Statutory UK Legal Framework
Medical practitioners must understand the statutory boundaries governing patient autonomy, consent, capacity, and compulsory psychiatric intervention under UK law.
Mental Capacity Act 2005 (England & Wales)
The Mental Capacity Act (MCA) 2005 governs decision-making on behalf of individuals aged 16 and older who lack decision-making capacity.
Five Core Statutory Principles:
Presumption of Capacity: Every individual is assumed to have capacity unless proven otherwise.
Support to Make Decisions: A person cannot be treated as unable to make a decision unless all practicable steps to help them do so have failed.
Right to Make Unwise Decisions: An eccentric, irrational, or unwise decision does not in itself establish a lack of capacity.
Best Interests: Any act done or decision made on behalf of an incapacitated person must be in their best interests.
Least Restrictive Alternative: Interventions must restrict the person's rights and freedom of action as little as possible.
Two-Stage Functional Test of Capacity:
Capacity is strictly decision-specific and time-specific (a patient may have capacity to choose their lunch or consent to venepuncture, but lack capacity to consent to a complex surgical procedure or refuse life-saving dialysis).
Stage 1 (Diagnostic Threshold): Does the person have an impairment of, or a disturbance in the functioning of, the mind or brain (temporary or permanent, e.g. delirium, dementia, intoxication, head injury, acute psychosis)?
Stage 2 (Functional Assessment): Does that impairment render the person unable to perform ANY of the following four functional steps?
Understand the information relevant to the decision (including benefits, risks, and consequences of refusing).
Retain that information long enough to make the decision.
Use or weigh that information as part of the process of making the decision.
Communicate their decision (by speech, sign language, blinking, or any other means).
Best Interests Determinations & Legal Proxies:
When a patient lacks capacity, clinicians make decisions under the MCA using a structured Best Interests checklist (considering the patient's past/present wishes, beliefs, values, and consulting family/carers).
Lasting Power of Attorney (LPA) for Health and Welfare: Legally appointed proxy who can make medical decisions only when the patient lacks capacity. Cannot override life-sustaining treatment unless specifically authorized in the registered LPA deed.
Advance Decision to Refuse Treatment (ADRT): Legally binding refusal of specific treatments. To apply to life-sustaining treatment, it must be in writing, signed, witnessed, and explicitly state "even if life is at risk" . A valid and applicable ADRT overrides best interests decisions.
Independent Mental Capacity Advocate (IMCA): Statutory advocate required when an unbefriended patient lacking capacity faces serious medical treatment decisions or long-term care moves.
Deprivation of Liberty Safeguards (DoLS) / Liberty Protection Safeguards (LPS):
Applied when an incapacitated adult is deprived of liberty in a hospital or care home.
Defined by the Supreme Court Cheshire West "Acid Test" : The person is (1) subject to continuous supervision and control , AND (2) not free to leave , AND (3) lacks capacity to consent to those arrangements.
Mental Health Act 1983 (Amended 2007)
The Mental Health Act (MHA) provides statutory powers for the compulsory detention and treatment of individuals with a mental disorder who pose a significant risk to their own health, safety, or to others.
Key Statutory Sections for the Medical Ward:
Section 2 (Assessment): Admission for assessment (and treatment) of mental disorder. Duration: Up to 28 days (cannot be extended or renewed). Requires recommendations from two medical practitioners (one of whom must be approved under Section 12, e.g. a consultant psychiatrist) plus an Approved Mental Health Professional (AMHP) or nearest relative.
Section 3 (Treatment): Admission for treatment of a confirmed mental disorder where appropriate medical treatment is available. Duration: Up to 6 months (renewable). Requires two medical practitioners (one Section 12 approved) plus an AMHP.
Section 4 (Emergency Admission): Emergency admission for assessment when Section 2 would cause unacceptable delay. Duration: Up to 72 hours . Requires one medical practitioner (preferably knowing the patient) and an AMHP. Converts to Section 2 upon second medical recommendation.
Section 5(2) (Doctor's Holding Power): Detains an informal inpatient already admitted to a hospital bed (medical, surgical, or psychiatric ward) who expresses intent to leave and meets detention criteria. Duration: Up to 72 hours (non-renewable). Completed by the registered medical practitioner in charge of the patient's treatment or their nominated deputy. Cannot be used in the Emergency Department (A&E is not an inpatient ward) or on outpatients.
Section 5(4) (Nurse's Holding Power): Applied by an authorized mental health or learning disability nurse to detain an informal inpatient up to 6 hours while awaiting a medical practitioner to complete Section 5(2).
CRITICAL LEGAL BOUNDARY: Physical vs Psychiatric Treatment
A foundational MRCP Part 1 principle: The Mental Health Act CANNOT be used to enforce treatment for purely physical medical conditions (e.g. antibiotic therapy for sepsis, emergency laparotomy, percutaneous coronary intervention, insulin for DKA) against a competent patient's refusal, or on an incompetent patient whose physical illness is unrelated to their mental disorder.
Single Exception: Physical treatment is permissible under the MHA only if it is directly treating, or is an integral physical consequence of, the mental disorder itself (e.g. nasogastric refeeding for life-threatening anorexia nervosa, or suturing a self-inflicted wound immediately following a psychotic act).
Refusal of Physical Treatment: If an inpatient refuses physical medical care:
Assess decision-specific capacity under the Mental Capacity Act 2005 .
If the patient has capacity → their refusal must be respected, even if it results in death.
If the patient lacks capacity (e.g. due to delirium, dementia, or severe psychosis impairing ability to weigh physical risk) → provide necessary physical medical treatment in their Best Interests under the Mental Capacity Act 2005 , using the least restrictive means.